Login / Signup

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.

Laura PizzutiEriseld KrasniqiIsabella SperdutiMaddalena BarbaTeresa GamucciMaria MauriEnzo Maria VeltriIcro MeattiniRossana BerardiFrancesca Sofia Di LisaClara NatoliMirco PistelliLaura IezziEmanuela RisiNicola D'OstilioSilverio TomaoCorrado FicorellaKatia CannitaFerdinando RiccardiAlessandra CassanoEmilio BriaMaria Agnese FabbriMarco MazzottaGiacomo BarchiesiAndrea BotticelliGiuliana D'AuriaAnna CeribelliAndrea MichelottiAntonio RussoBeatrice Taurelli SalimbeniGiuseppina SarobbaFrancesco GiottaIda ParisRosa SaltarelliDaniele MarinelliDomenico CorsiElisabetta Maria CapomollaValentina SiniLuca MoscettiLucia MentucciaGiuseppe ToniniMimma RaffaeleLuca MarchettiMauro MinelliEnzo Maria RuggeriPaola ScavinaOlivia BacciuNello SalesiLorenzo LiviNicola TinariAntonino GrassadoniaAngelo Fedele ScintoRosalinda RossiMaria Rosaria ValerioElisabetta LanducciSimonetta StaniBeatrice FratiniMarcello Maugeri-SaccàMichele De TursiAngela MaioneDaniele SantiniArmando OrlandiVito LorussoEnrico CortesiGiuseppe SanguinetiPaola PinnaròFederico CappuzzoLorenza LandiClaudio BottiFederica TomaoSonia CappelliGiulia BonFabio PelleFlavia CavicchiElena FiorioJennifer FogliettaSimone ScagnoliPaolo MarchettiGennaro CilibertoPatrizia Vici
Published in: Therapeutic advances in medical oncology (2021)
Our results confirmed a relevant impact of first-line pertuzumab-based treatment and showed lower efficacy of second-line T-DM1 in trastuzumab/pertuzumab pretreated, as compared with pertuzumab-naïve patients. Our findings may help delineate a more appropriate therapeutic strategy in HER2-positive metastatic BC. Prospective randomized trials addressing this topic are awaited.
Keyphrases